In focus
Latest feed
Veradermics Steps Onto the Public Stage: A Deep Dive into Their $200 Million IPO Bet
Corvus Pharmaceuticals Takes Key Step Forward with Lead Eczema Drug
Regeneron's Remarkable Resurgence: Charting the Course of a Biotech Comeback
The Dermatological Revolution: Unpacking the Promise and Peril of Tomorrow's Treatments
